Statins exert pleiotropic effects on the cardiovascular system, in part through an increase in nitric oxide (NO) bioavailability. In this study, we examined the role of pravastatin in ischemia-induced angiogenesis. Unilateral hindlimb ischemia was surgically induced in C57BL/6J mice. Phosphorylation of AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC) and endothelial NO synthase (eNOS) was increased in ischemic tissues. Furthermore, mice treated with pravastatin showed higher increases in phosphorylation than did untreated mice. Laser Doppler analysis has shown that pravastatin treatment accelerates the development of collateral vessels and angiogenesis in response to hindlimb ischemia. Capillary density in the ischemic hindlimb was also increased by pravastatin treatment. An in vitro study on human umbilical vein endothelial cells (HUVECs) revealed that pravastatin increased the phosphorylation of AMPK. Pravastatin-induced phosphorylation of eNOS, one of the downstreams of AMPK, was inhibited by compound C, an AMPK antagonist. The increased migration and tube formation of HUVECs by pravastatin were significantly blocked by compound C treatment. The accelerated angiogenesis by pravastatin after hindlimb ischemia was significantly reduced after treatment with compound C. Thus, ischemia induced AMPK phosphorylation in vivo. Furthermore, pravastatin could also activate AMPK in vivo and in vitro. Such phosphorylation results in eNOS activation and angiogenesis, which provide a novel explanation for one of the pleiotropic effects of statins that is beneficial for angiogenesis. Keywords: angiogenesis; endothelium; ischemia; nitric oxide synthase; statins
INTRODUCTION
The AMP-activated protein kinase (AMPK) is a trimeric enzyme comprising a catalytic a-subunit and regulatory-b, g-subunits. AMPK was identified as an upstream kinase that phosphorylates and hence inactivates 3-hydroxy-3-methylglutaryl-coenzyme A reductase and acetyl-coenzyme A carboxylase (ACC), key enzymes that control choresterol/isoprenoid and fatty acid biosynthesis, respectively. AMPK is considered to be a cellular energy sensor that stimulates ATP-producing catabolic pathways and inhibits ATP-consuming anabolic pathways. 1 Thus, the AMPK pathway is thought to be a regulator of stress responses and cellular energy homeostasis. However, recent studies have shown that AMPK also plays an important role in maintaining endothelial functions. 2 AMPK activation has beneficial effects on endothelial functions and in antiatherogenesis. These effects include the induction of the endothelial nitric oxide synthase (eNOS) pathway to increase NO bioavailability; the suppression of endothelial reactive oxygen species production when stimulated by hyperglycemia or high free fatty acids to improve endothelial free fatty acid oxidation and limit lipid accumulation; the inhibition of apoptosis and inflammation; and the modulation of the vascular tone. 3, 4 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) belong to the class of lipid-lowering medications. Numerous studies, however, suggest that statin therapy has additional cardiovascular protective effects that may function independently of their ability to lower serum cholesterol levels. 5, 6 In addition, the antithrombotic and anti-inflammatory effects of statins have been shown to contribute to the overall beneficial activity of these drugs. 7 Most importantly, statin therapy improves endothelial function by virtue of its antioxidant and anti-inflammatory effects, 8, 9 as well as by its ability to upregulate eNOS. 10 The statin activation of Akt has been shown to inhibit apoptosis, acutely increase NO production, induce migration and promote angiogenesis. 11 These effects of statins were prevented by PI3K inhibitors or by the dominant-negative form of Akt. 11 Although many studies have reported that these effects depend on eNOS activation by Akt, their action cannot be explained by Akt activation alone. 12 Indeed, each physiological response downstream of Akt seems to be mediated by multiple targets.
Recent studies have reported that statins can activate AMPK in mouse aorta and myocardium. 13 Furthermore, AMPK signaling is required for angiogenic responses in endothelial cells (ECs) under hypoxic conditions in vitro. 14 In addition, adiponectin or 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) and AMPK activators promote angiogenesis in response to ischemic stress. 15, 16 Furthermore, atrovastatin-induced eNOS phosphorylation was attenuated in the aorta of AMPKa2 À/À mice. 17 Thus, eNOS phosphorylation may be at least partly mediated by AMPK activation. However, the molecular mechanism of angiogenesis by statins is not fully understood. Here, we investigated the role of AMPK in statininduced eNOS phosphorylation in vitro and in vivo. Our results show that pravastatin can activate AMPK in an ischemic hindlimb, with the assistance of eNOS.
METHODS Materials
Pravastatin was provided as a gift from Daiichi Sankyo Co. Ltd. (Tokyo, Japan). The antibodies used in this study and their commercial sources were as follows: anti-phospho-AMPK (p-Thr172), anti-AMPK, anti-phospho-Akt (p-Ser473), anti-Akt, anti-phospho-ACC (p-Ser79), anti-ACC and anti-phospho-eNOS (p-Ser1177) (Cell Signaling Technology, Beverly, MA, USA); antieNOS (BD Biosciences, San Jose, CA, USA); anti-b-actin (SIGMA, St Louis, MO, USA); and the horseradish-peroxidase-coupled secondary antibodies (GE Healthcare, Chalfont St Giles, UK). Compound C, an AMPK inhibitor, was purchased from Calbiochem (San Diego, CA, USA). Matrigel was obtained from BD Biosciences.
Animal experiments
All procedures were in accordance with the institutional guidelines for animal research. All experiments were performed using male C57BL/6J mice aged 8-9 weeks (Japan CREA, Tokyo, Japan). Unilateral hindlimb ischemia was induced by resecting the left femoral arteries and veins of mice under anesthesia with sodium pentobarbital (50 mg kg À1 intraperitoneally), as described previously. 18 In the first experiment, we examined the time course of ischemia-induced AMPK, eNOS and Akt activities. Next, the mice were fed with pravastatin at 20 mg kg À1 body weight by gastric gavage. Saline was fed to control animals as control. After 4, 8, 16 or 24 h, the mice were killed and their hindlimbs were removed and stored in À80 1C for western blotting. Furthermore, hindlimb ischemia was induced after 7 h of pravastatin administration by gastric gavage, and the mice were killed after 60 min of ischemia induction.
In the second experiment, to investigate the effect of pravastatin on hindlimb blood flow, the mice were administered pravastatin (20 mg kg À1 day À1 ) in drinking water from the day of ischemia induction.
Laser Doppler blood flow analysis
Hindlimb blood flow was measured using a laser Doppler blood flow (LDBF) analyzer (Moor LDI; Moor Instruments, Axminster, UK) as described previously. 18 Before the operation and on postoperative days 4, 7, 14, 21 and 28, we performed LDBF analysis on the legs and feet. After scanning the blood flow twice, the stored images were subjected to computer-assisted quantification, and the average flows of the ischemic and non-ischemic limbs were calculated. To avoid data variations due to ambient light and temperature, hindlimb blood flow was expressed as the ratio of left (ischemic) to right (non-ischemic) LDBF.
Capillary density
Capillary density within the ischemic thigh adductor skeletal muscles was analyzed to obtain a specific evidence of vascularity at the microcirculation level, similar to our previous method. 18 Three pieces of ischemic muscles were harvested from each animal, sliced and fixed in methanol. The tissues were embedded in paraffin, and multiple tissue slices of 5 mm thickness were prepared. Capillary ECs were identified by immunohistochemical staining with a rat anti-mouse CD31 antibody (Ab) (BD Biosciences). Fifteen random microscopic fields from three different sections in each tissue block were examined for the presence of capillary ECs, and capillary density was expressed as the number of capillaries per high-power field (Â400).
Preparation of extracts and western blot analysis
Our detailed method has been previously described. 18, 19 Protein extracts were obtained from homogenized ischemic or non-ischemic skeletal muscles. After an electrophoretic transfer to polyvinylidine difluoride membranes (Immobilon-P, Millipore, Billerica, MA, USA), the membranes were probed with each primary antibody.
Effects of AMPK inhibitor on ischemia-induced angiogenesis
Mice were injected intraperitoneally with 10 mg kg À1 of compound C dissolved in DMSO (Wako Chemicals, Osaka, Japan) or with DMSO alone before inducing ischemia thrice weekly. We measured hindlimb blood flow until day 28, as mentioned above.
Cell culture, migration and tube formation EGM2 and EBM2, culture media and human umbilical vein ECs (HUVECs, passage 3-5) were purchased from Lonza (Basel, Switzerland). The cells were cultured at 37 1C, in 5% CO 2 in EGM2 medium. Three mmol l À1 of compound C was treated before 30 min of pravastatin stimulation. All experiments were performed at least four times repeatedly.
The cells were washed with phosphate-buffered saline and lysed in RIPA buffer containing 50 mmol l À1 HEPES (pH 8.0), 150 mmol l À1 NaCl, 5 mmol l À1 EDTA, 1% CHAPS, 10% glycerol, 100 mmol l À1 NaF, 0.2 mmol l À1 DTT, 1 mmol l À1 phenylmethylsulfonyl fluoride, protease inhibitor cocktail (Nacalai Tesque, Osaka, Japan) for western blotting.
Transwell inserts (Nalgen Nunc, Rochester, NY, USA) were coated with 0.1 mg ml À1 collagen. Pravastatin (1 mmol l À1 ) dissolved in EBM-2 medium containing 0.25% bovine serum albumin was added to the bottom chamber of the Boyden apparatus. HUVECs (1Â10 5 cells) suspended in a 100 ml aliquot of EBM-2 containing 0.25% bovine serum albumin were added to the upper chamber. After 5 h incubation, the non-migrating cells in the upper part of the chamber were removed mechanically, and the remaining cells on the lower part were fixed with methanol. The migrated cells were counted in six random microscopic fields after staining with Diff-Quik solutions (Sysmex International Reagents Co. Ltd, Kobe, Japan).
The formation of vascular-like structures by HUVECs was assessed on growth factor-reduced Matrigel (BD Biosciences). Cells were plated at 1Â10 4 well À1 in a 96-well-multidish, precoated with 30 ml of Matrigel in the absence or presence of pravastatin (1 mmol l À1 ). After 5 h, the length of the completed tube-like structure in the center field (magnification, Â10) was quantified. Images were captured with a CCD color camera attached to the microscope and the tube length was measured using a Micro Analyzer (JPD, Tokyo, Japan).
Statistical analysis
All data are presented as mean ± s.e.m. Comparisons among groups were made by one-way analysis of variance. For differences between two groups, Student's t-test was used when appropriate. Differences were considered statistically significant at a value of Po0.05.
RESULTS
Time course of AMPK activation after ischemia and pravastatin treatment All mice survived after the surgical induction of unilateral hindlimb ischemia. We investigated AMPK, Akt and eNOS activities in ischemic hindlimb. As shown in Figure 1a , AMPK was remarkably activated at 15 min after hindlimb ischemia and peaked at 60 min. Akt and eNOS activities were also increased in response to ischemia. The level of phosphorylated AMPK in the hindlimb increased 4 h after pravastatin administration and lasted for at least 24 h (Figure 1b) . The phosphorylation of ACC, Akt and eNOS was elevated. Therefore, we next examined the effect of pravastatin on the phosphorylation of AMPK, ACC, Akt and eNOS in the ischemic tissue. AMPK phosphorylation after 60 min of ischemia induction was additionally increased with pravastatin administration (Figure 1c) . The level of AMPK and b-actin was not changed.
Unilateral hindlimb ischemia and time course of LDBF analysis
Immediately after the left femoral artery and vein were resected, the ratio of ischemic (left) to non-ischemic (right) hindlimb LDBF (the LDBF ratio) decreased from 1.06 ± 0.05 to 0.08 ± 0.01 without pravastatin and from 1.00 ± 0.01 to 0.10 ± 0.01 with pravastatin. Thus, the severity of induced ischemia was comparable in the two groups. Figure 2a shows the representative LDBF images of hindlimb blood flow. A serial LDBF examination disclosed a progressive recovery of hindlimb blood flow in the pravastatin-untreated mice after ischemia was induced. On the other hand, the blood flow of mice treated with pravastatin was accelerated during the follow-up period. Compared with control mice, the LDBF ratio in the pravastatin-treated mice was persistently high after 4 days following the induction of ischemia, and significantly increased except on day 14 (Po0.05) (Figure 2b ).
Tissue capillary density
To investigate the extent of angiogenesis at the microcirculation level, we measured capillary density in histological sections harvested from ischemic tissues. Quantitative analysis revealed that the capillary density was significantly augmented by pravastatin on postoperative day 28, compared with that in control mice (Figure 2c ).
Effects of compound C on pravastatin-induced eNOS phosphorylation, migration and tube formation in HUVECs
To determine whether AMPK activation is directly concerned with endothelial functions, we studied the effects of compound C, an AMPK inhibitor, on angiogenesis. Angiogenesis incorporates migration, intercellular connections with other ECs and lumen formation in vitro. Angiogenesis was assessed by tube formation assay using Matrigel. Compound C (3 mmol l À1 ) significantly inhibited pravastatin-induced tube formation ( Figure 3a) . As angiogenesis involves cell migration, we investigated the role of compound C in the pravastatininduced migration of HUVECs, using a modified Boyden chamber method. Compound C treatment inhibited pravastatin-induced cell migration (Figure 3b ). AMPK phosphorylation after 60 min of ischemia induction was further increased after pravastatin administration (after 8 h). pAMPK, phospho-AMPK; pAkt, phospho-Akt; peNOS, phospho-eNOS; pACC, phospho-ACC; Prava, pravastatin; N, non-ischemic muscle; I, ischemic muscle. 
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As eNOS activation is important in endothelial function, we next measured the phosphorylation of eNOS. Pravastatin (1 mmol l À1 ) induced the phosphorylation of eNOS at Ser1177, which could be blocked by compound C pretreatment for 30 min (Figure 3c ). Taken together, these results suggest that blockade of AMPK suppressed angiogenesis, which indicates that endogenous AMPK is important for the angiogenic activity of ECs.
In vivo blockade of AMPK weakens angiogenesis
We finally examined the effect of compound C on pravastatin-induced angiogenesis in vivo. The recovery of hindlimb blood flow in mice treated with compound C was weaker than that in control (DMSO)-treated mice after 14 days following the induction of ischemia. The increased LDBF ratio by pravastatin administration was also reduced with compound C (Figure 4a ). On postoperative day 28, the increase in capillary density by pravastatin was also reduced with the treatment of compound C (Figure 4b ).
DISCUSSION
In this study, angiogenesis and blood flow recovery in response to hindlimb ischemia were significantly advanced by pravastatin, and increased angiogenesis was blocked by compound C. Thus, pravastatin displays proangiogenic effects through AMPK-eNOS activation on ECs.
Recent studies have suggested that AMPK is necessary for hypoxiainduced VEGF mRNA stabilization, and regulates VEGF expression and capillarization. 20, 21 Furthermore, recent reports state that statins reduce cardiovascular events and enhance ischemia-induced angiogenesis. 11, 12, 22 In this study, we investigated whether the statin activation of AMPK involved angiogenesis.
We used pravastatin to demonstrate the positive effect of statins on the phosphorylation of AMPK (Thr172) in ECs. Such phosphorylation is essential for AMPK activation, which is also demonstrated by increased AMPK activity and increased phosphorylation of ACC (Ser79), a direct target of AMPK. 23 Other statins such as atrovastatin and lovastatin can also cause AMPK and ACC phosphorylation in ECs. 13 Furthermore, Xenos et al. 24 showed that the level of AMPK protein in human ECs increased following 48 h of fluvastatin treatment. On the other hand, AMPK phosphorylation in ECs was increased by statins in a rapid and transient manner. This temporal response is similar to that stimulated by shear stress, by adiponectin and by metformin. [25] [26] [27] [28] Sun et al. 13 showed that the phosphorylation/ activation of AMPK in mouse aorta and myocardium was observed as early as 2 h and peaked at 4-8 h after atrovastatin administration. However, the role of AMPK in angiogenesis in vivo has not been fully elucidated. The present data indicate that AMPK was transiently phosphorylated by ischemia (Figure 1a) . Furthermore, the phosphorylation of AMPK in the mouse hindlimb was observed as early as 4 h and peaked at 16-24 h after pravastatin administration (Figure 1b) . From this finding and from the report stating that activated AMPK in muscle induces VEGF production and promotes angiogenesis, 16 the tissues in which AMPK activation was observed in the hindlimb in vivo were the endothelium and mycocytes.
The effect of statins on eNOS activation in ECs is dependent on the phosphatidylinositol-3 kinase (PI3K)-Akt pathway. 11, 29 Our data indicate that AMPK is also engaged in the upregulation of eNOS by pravastatin. The association between Akt and AMPK in eNOS phosphorylation (Ser 1177) is elusive. 30 Dimmeler et al. 29 have shown that shear stress-induced eNOS phosphorylation was blocked by a PI3K inhibitor, wortmannin, in ECs. On the other hand, Chen et al. 25 have shown that a dominant-negative mutant of AMPK (DN-AMPK), but not of Akt, significantly inhibited eNOS phosphorylation and NO production in ECs in response to adiponectin. Very recently, Sun et al. 13 have shown that eNOS phosphorylation in HUVECs was inhibited by DN-AMPK or by compound C, whereas Akt phosphorylation was drastically increased by the downregulation of AMPK. Our present data support the hypothesis that eNOS activation depends not only on Akt but also on AMPK, because inhibition of AMPK attenuated statin-activated eNOS. A recent study 17 that atrovastatin-induced eNOS phosphorylation was attenuated in AMPKa2 À/À mice supports our results. On the other hand, Ouchi et al. 26 have shown that DN-Akt blocked adiponectin-stimulated Akt and eNOS phosphorylation without altering AMPK phosphorylation, whereas DN-AMPK inhibited adiponectin-induced Akt phosphorylation. These results suggest that AMPK may be upstream of Akt. n, pravastatin; m, pravastatin and compound C; C.C, compound C; pAMPK, phospho-AMPK; pAkt, phospho-Akt; peNOS, phospho-eNOS; pACC, phospho-ACC; Prava, pravastatin; N, non-ischemic muscle; I, ischemic muscle. Each bar represents mean ± s.e.m. (n¼5-6). *Po0.05 vs. vehicle.
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The AMP-activated protein kinase seems to play a central role in metabolic regulations as its activation improves metabolic abnormalities that are found in diabetic mice and rats. 31, 32 Transgenic mice expressing a kinase-dead mutant of AMPK showed increased apoptosis and cardiac dysfunction after an ischemia-reperfusion injury. 33 Furthermore, adiponectin has been shown to protect the heart from ischemia-reperfusion injury through the AMPK pathway. 34 We found that compound C significantly decreased pravastatin-induced eNOS phosphorylation in HUVECs, thereby confirming that pravastatin regulates eNOS activity through AMPK. Thus, the pharmacological activators of AMPK signaling could produce beneficial effects. In addition, the effects of statin-activated AMPK could extend beyond the protection of the vascular endothelium.
In conclusion, our present work has provided the first in vivo evidence that angiogenesis and blood flow recovery in response to hindlimb ischemia are accelerated by pravastatin and that the increased angiogenesis is blocked by compound C. Thus, pravastatin will have proangiogenic effects through AMPK-eNOS activation on ECs. These findings suggest that AMPK could be a new therapeutic target for vascular diseases.
